Northern Indiana Cancer Research Consortium No. Indiana Cancer Res.

South Bend, Indiana 46617

0 studies enrolling now · 3 studies all time

What they study most

Hematologic Malignancies, PI3K Pathway Activated Tumors, Solid Tumor, Tumors With CDK4/6 Pathway Activation

Studies at this site

• LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) — Completed
• BGJ398 for Patients With Tumors With FGFR Genetic Alterations — Stopped early
• BKM120 for Patients With PI3K-activated Tumors — Completed